{
    "id": 27991,
    "fullName": "RB1 V654fs",
    "impact": "frameshift",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "RB1 V654fs results in a change in the amino acid sequence of the Rb1 protein beginning at aa 654 of 928, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), V654fs is predicted to lead to a loss Rb1 protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5925,
        "geneSymbol": "RB1",
        "terms": [
            "RB1",
            "OSRC",
            "p105-Rb",
            "p110-RB1",
            "pp110",
            "PPP1R130",
            "pRb",
            "RB"
        ]
    },
    "variant": "V654fs",
    "createDate": "05/01/2018",
    "updateDate": "05/01/2018",
    "referenceTranscriptCoordinates": {
        "id": 147653,
        "transcript": "NM_000321",
        "gDna": "chr13:g.(48456348_48456349)",
        "cDna": "c.(1960_1959)",
        "protein": "p.V654fs",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13827,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, RB1 mutations including E268*, I101fs, T738_R775del, and V654fs were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 8 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).",
            "molecularProfile": {
                "id": 29570,
                "profileName": "RB1 I101fs RB1 E268* RB1 V654fs RB1 T738_R775del"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11295,
                    "pubMedId": 29236940,
                    "title": "Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29236940"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29561,
            "profileName": "RB1 V654fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29570,
            "profileName": "RB1 I101fs RB1 E268* RB1 V654fs RB1 T738_R775del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 147653,
            "transcript": "NM_000321",
            "gDna": "chr13:g.(48456348_48456349)",
            "cDna": "c.(1960_1959)",
            "protein": "p.V654fs",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}